Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer

被引:1
作者
Yamazaki, Hideya [1 ]
Suzuki, Gen [1 ]
Aibe, Norihiro [1 ]
Shimizu, Daisuke [1 ]
Kimoto, Takuya [1 ]
Masui, Koji [1 ]
Yoshida, Ken [2 ]
Nakamura, Satoaki [2 ]
Hashimoto, Yasutoshi [3 ]
Okabe, Haruumi [3 ]
机构
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Radiol, Kamigyo Ku, 465 Kajiicho Kawaramachi Hirokoji, Kyoto 6028566, Japan
[2] Kansai Med Univ, Dept Radiol, Hirakata, Osaka 5731010, Japan
[3] Ujitakeda Hosp, Dept Radiol, Uji, Kyoto 6110021, Japan
关键词
prostate cancer; ultrahypofractionation; late toxicity; radiotherapy; BODY RADIATION-THERAPY; TOXICITY; TRIAL;
D O I
10.3390/cancers14010195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Recently, shortening treatment time is becoming more important. Ultrahypofractionated radiotherapy (UHF) for localized prostate cancer is a fascinating treatment strategy; however, the concept of a well-balanced, optimal dose during UHF radiotherapy remains a contentious strategy, with only a few studies on UHF already reported. We must wait for the results of randomized trials several years away. Therefore, we tried to reveal the acceptable schedule in comparison to conventional to moderate hypofractionated radiotherapy so far. We found that UHF using EQD2 <= 100 Gy(1.5) is a feasible UHF schedule with a good balance between toxicity and efficacy. The purpose of this study was to compare the toxicity (first endpoint) and efficacy (second endpoint) of ultrahypofractionated radiotherapy (UHF) and dose-escalated conventional to moderate hypofractionated radiotherapy (DeRT) for clinically localized prostate cancer. We compared 253 patients treated with UHF and 499 patients treated with DeRT using multi-institutional retrospective data. To analyze toxicity, we divided UHF into High-dose UHF (H-UHF; equivalent doses of 2 Gy per fraction: EQD2 > 100 Gy(1.5)) and low-dose UHF (L-UHF; EQD2 <= 100 Gy(1.5)). In toxicity, H-UHF elevated for 3 years accumulated late gastrointestinal and genitourinary toxicity grade >= 2 (11.1% and 9.3%) more than L-UHF (3% and 1.2%) and DeRT (3.1% and 4.8%, p = 0.00126 and p = 0.00549). With median follow-up periods of 32.0 and 61.7 months, the actuarial 3-year biochemical failure-free survival rates were 100% (100% and 100% in the L-UHF and H-UHF) and 96.3% in the low-risk group, 96.5% (97.1% and 95.6%) and 94.9% in the intermediate-risk group, and 93.7% (100% and 94.6%) and 91.7% in the high-risk group in the UHF and DeRT groups, respectively. UHF showed equivocal efficacy, although not conclusive but suggestive due to a short follow-up period of UHF. L-UHF using EQD2 <= 100 Gy(1.5) is a feasible UHF schedule with a good balance between toxicity and efficacy.
引用
收藏
页数:13
相关论文
共 30 条
[1]   SBRT for the primary treatment of localized prostate cancer: the effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines [J].
Bernetich, Matthew ;
Oliai, Caspian ;
Lanciano, Rachelle ;
Hanlon, Alexandra ;
Lamond, John ;
Arrigo, Stephen ;
Yang, Jun ;
Good, Michael ;
Feng, Jing ;
Brown, Royce ;
Garber, Bruce ;
Mooreville, Michael ;
Brady, Luther W. .
FRONTIERS IN ONCOLOGY, 2014, 4
[2]   Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial [J].
Brand, Douglas H. ;
Tree, Alison C. ;
Ostler, Peter ;
van der Voet, Hans ;
Loblaw, Andrew ;
Chu, William ;
Ford, Daniel ;
Tolan, Shaun ;
Jain, Suneil ;
Martin, Alexander ;
Staffurth, John ;
Camilleri, Philip ;
Kancherla, Kiran ;
Frew, John ;
Chan, Andrew ;
Dayes, Ian S. ;
Henderson, Daniel ;
Brown, Stephanie ;
Cruickshank, Clare ;
Burnett, Stephanie ;
Duffton, Aileen ;
Griffin, Clare ;
Hinder, Victoria ;
Morrison, Kirsty ;
Naismith, Olivia ;
Hall, Emma ;
van As, Nicholas .
LANCET ONCOLOGY, 2019, 20 (11) :1531-1543
[3]   Dosimetric and radiobiological comparison of Cyberknife and Tomotherapy in stereotactic body radiotherapy for localized prostate cancer [J].
Chen, Chun-You ;
Lee, Liang-Ming ;
Yu, Hsiao-Wei ;
Lee, Steve P. ;
Lee, Hsin-Lun ;
Lin, Yung-Wei ;
Wen, Yu-Ching ;
Chen, Yi-Ju ;
Chen, Chiu-Ping ;
Tsai, Jo-Ting .
JOURNAL OF X-RAY SCIENCE AND TECHNOLOGY, 2017, 25 (03) :465-477
[4]   Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience [J].
Chen, Leonard N. ;
Suy, Simeng ;
Uhm, Sunghae ;
Oermann, Eric K. ;
Ju, Andrew W. ;
Chen, Viola ;
Hanscom, Heather N. ;
Laing, Sarah ;
Kim, Joy S. ;
Lei, Siyuan ;
Batipps, Gerald P. ;
Kowalczyk, Keith ;
Bandi, Gaurav ;
Pahira, John ;
McGeagh, Kevin G. ;
Collins, Brian T. ;
Krishnan, Pranay ;
Dawson, Nancy A. ;
Taylor, Kathryn L. ;
Dritschilo, Anatoly ;
Lynch, John H. ;
Collins, Sean P. .
RADIATION ONCOLOGY, 2013, 8
[5]   Photons, Protons, SBRT, Brachytherapy-What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team [J].
Choudhury, Ananya ;
Henry, Ann ;
Mitin, Timur ;
Chen, Ronald ;
Joseph, Nuradh ;
Spratt, Daniel E. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (04) :1114-1121
[6]   Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT [J].
de Chavez, Romena ;
Grogan, Garry ;
Hug, Ben ;
Howe, Kate ;
Grigg, Alice ;
Waterhouse, David ;
Lane, Jonathan ;
Glyde, Alan ;
Brown, Elizabeth ;
Bydder, Sean ;
Pryor, David ;
Hargrave, Cathy ;
Charles, Paul H. ;
Hellyer, James ;
Ebert, Martin A. .
MEDICAL DOSIMETRY, 2022, 47 (01) :61-69
[7]   Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose? [J].
Helou, Joelle ;
D'Alimonte, Laura ;
Quon, Harvey ;
Deabreu, Andrea ;
Commisso, Kristina ;
Cheung, Patrick ;
Chu, William ;
Mamedov, Alexandre ;
Davidson, Melanie ;
Ravi, Ananth ;
Loblaw, Andrew .
RADIOTHERAPY AND ONCOLOGY, 2017, 123 (03) :478-482
[8]   Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients [J].
Ishiyama, Hiromichi ;
Tsumura, Hideyasu ;
Nagano, Hisato ;
Watanabe, Motoi ;
Mizuno, Eiichi ;
Taka, Masashi ;
Kobayashi, Hiroaki ;
Eriguchi, Takahisa ;
Imada, Hajime ;
Inaba, Koji ;
Nakamura, Katsumasa .
SCIENTIFIC REPORTS, 2021, 11 (01)
[9]   A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer [J].
Kainuma, Takuro ;
Kawakami, Shogo ;
Tsumura, Hideyasu ;
Satoh, Takefumi ;
Tabata, Ken-ichi ;
Iwamura, Masatsugu ;
Hayakawa, Kazushige ;
Ishiyama, Hiromichi .
RADIATION ONCOLOGY, 2019, 14 (01)
[10]   Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].
Kanda, Y. .
BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458